Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynamin-binding protein (DNMBP), also known as ARHGEF36, KIAA1010, and Tuba, is a guanine nucleotide exchange factor (GEF) that primarily activates CDC42, a member of the Rho GTPase family[1][2][4]. DNMBP serves as a scaffold protein, facilitating interactions between dynamin and actin regulatory proteins to organize the actin and microtubule cytoskeleton essential for cell structure and signaling[2][7]. It is involved in regulating the structure of apical junctions in epithelial cells through F-actin organization, spindle orientation during lumenogenesis, and possibly ciliogenesis and membrane trafficking[1][2][5]. DNMBP gene polymorphisms have been linked to certain cataract types and may be associated with susceptibility to Alzheimer’s disease in specific populations, though with conflicting evidence[2]. Alternative splicing results in multiple transcript variants for this protein[2]. DNMBP forms part of cellular pathways involving Rho GTPase signaling, essential for cytoskeletal dynamics and cell junction configuration[2][4]. It is considered a molecular target due to its role as a GEF in signaling pathways relevant to disease and cell biology[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynamin-binding protein (DNMBP).